Price movement over the last 24 hours
Alcon AG vs Booking Holdings Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Booking Holdings Inc trades at $174.54 (market cap $140.99B). The key difference: Booking Holdings Inc is far larger — about 4.3× Alcon AG's market cap, and Booking Holdings Inc pays the higher dividend (0.88%). Which is the better fit depends on your goals.
| ALC | BKNG | |
|---|---|---|
Market Cap | $32.69B | $140.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $231.02 |
52-Week Low | $62.02 | $154.13 |
Enterprise Value | $36.28B | $143.91B |
Dividend Yield | 0.54% | 0.88% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Booking Holdings (BKNG) trades at $181.95, down 1.41% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with 2025 revenue of $26.92B and net income margin of 22.23%, though Q2 2026 earnings are pending. Analyst consensus remains strongly positive with 64% buy ratings and a $225 price target, representing 24% upside potential from current levels.
BKNG presents a compelling investment case with robust cash flow generation ($9.4B operating cash flow in 2025) and dominant market position, though risks include high debt levels (64% debt-to-asset ratio) and AI disruption concerns. The stock's current valuation at 23.87 P/E appears reasonable given growth prospects, with upcoming Q2 earnings on August 4 serving as the next key catalyst.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →